FCF Healthcare & Life Sciences
Venture Capital Monitor
-
Europe

The FCF Healthcare & Life Sciences Venture Capital Monitor – Europe is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies, displaying Venture capital financing trends in the European Healthcare & Life Sciences industry.

FCF Healthcare & Life Sciences Venture Capital Monitor - Europe

As of the end of March 2025 we identified the following current VC trends in Europe:

  • Total Healthcare & Life Sciences funding reached EUR 3,713m (+55% vs. 2024)
  • Biotech/Pharma received 35% of the total investment volume (EUR 1,316m) with metabolic disorders being the leading indication (30%)
  • In March, Isomorphic Labs (United Kingdom) secured the highest transaction volume with EUR 536m, followed by Amboss (Germany) with EUR 240m and Augustine Therapeutics (Belgium) with EUR 78m
  • The Series A financing round of EUR 536m for Isomorphic Labs (United Kingdom) is the largest ever early-stage TechBio financing round in Europe
  • GV (United States) is the most active investor (by deal volume in 2025), followed by Alphabet (United States) and Thrive Capital (United States)

 

FCF Life Sciences Venture Capital Monitor - Europe
ETC.....

NEWS